登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002382 证券简称：蓝帆医疗 公告编号：2026-014 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 第六届董事会第三十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十九次会议于2026年2月14日以电子邮件 的方式发出通知，于2026年2月24日以通讯表决的方式召开。本次会议应参加会议董事8人，实际参加会 议董事8人，全体董事以通讯的方式出席会议。公司董事长刘文静女士主持了本次会议。会议的通知、 召开、表决程序符合《中华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议并通过了《关于董事会提议向下修正"蓝帆转债"转股价格的议案》； 截至2026年2月24日，公司股票已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股 价格85%的情形，已触发"蓝帆转债"转股价格向下修正条件。 为充分保护债券持有人利益，优化公司资本结构，支持公 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 （记者 曾健辉） 每经AI快讯，蓝帆医疗2月24日晚间发布公告称，公司第六届第三十九次董事会会议于2026年2月24日 以通讯表决的方式召开。会议审议了《关于召开2026年第二次临时股东会的议案》等文件。 每日经济新闻 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-015 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于董事会提议向下修正"蓝帆转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至 2026 年 2 月 24 日，蓝帆医疗股份有限公司（以下简称"公司"）股价 已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%的情 形，已触发"蓝帆转债"转股价格向下修正条件。 2、经公司第六届董事会第三十九次会议审议通过，公司董事会提议向下修正 "蓝帆转债"转股价格。 3、本次向下修正"蓝帆转债"转股价格的提议尚需提交公司股东会审议。 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 28 日公开发行了3,144.04 万张可转换公司债券（以下简称"可转债"），每张面值100 元，发 行总额314,404 万元。 （二）可转债上市情况 经深圳 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-016 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 3、会议召开的合法、合规性：本次股东会的召集、召开符合《中华人民共和国 公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及 《蓝帆医疗股份有限公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议时间：2026 年 3 月 16 日（星期一）下午 14：00 关于召开2026年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 经蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）第六届董事会第三 十九次会议审议通过，公司决定于 2026 年 3 月 16 日召开 2026 年第二次临时股东会， 现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2026 年第二次临时股东会 2、股东会的召集人：董事会 （2） ...

蓝帆医疗股份有限公司 第六届董事会第三十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十九次会议于 2026 年 2 月 14 日以电子邮件的方式发出通知，于 2026 年 2 月 24 日以通讯表决的方式召开。 本次会议应参加会议董事 8 人，实际参加会议董事 8 人，全体董事以通讯的方式出席 会议。公司董事长刘文静女士主持了本次会议。会议的通知、召开、表决程序符合《中 华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议并通过了《关于董事会提议向下修正"蓝帆转债"转股价格的议案》； | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-014 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 具体内容详见刊登于公司指定的信息披露媒体《中国证券报》、《上海证券报》、《证 券时报》、《证券日报》和巨潮资讯网（http://www.cninfo.co ...

近5日资金流向一览见下表： 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 蓝帆医疗2025年三季报显示，前三季度公司主营收入41.82亿元，同比下降10.15%；归母净利润-2.86亿 元，同比下降30.09%；扣非净利润-3.64亿元，同比下降46.25%；其中2025年第三季度，公司单季度主 营收入14.01亿元，同比下降15.02%；单季度归母净利润-1.51亿元，同比下降153.64%；单季度扣非净利 润-1.55亿元，同比下降151.16%；负债率41.01%，投资收益1348.2万元，财务费用1.4亿元，毛利率 13.66%。蓝帆医疗（002382）主营业务：心脑血管业务、健康防护业务、应急救护业务、新营销业 务。 证券之星消息，截至2026年2月12日收盘，蓝帆医疗(002382)报收于5.81元，下跌1.86%，换手率 0.85%，成交量8.53万手，成交额4982.41万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量 ...

Core Viewpoint - Bluefan Medical (002382) has reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations [2]. Financial Performance - For the first three quarters of 2025, Bluefan Medical's main revenue was 4.182 billion yuan, a year-on-year decrease of 10.15% [2]. - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year [2]. - The net profit excluding non-recurring items was -364 million yuan, reflecting a decline of 46.25% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 1.401 billion yuan, a decrease of 15.02% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -151 million yuan, a significant drop of 153.64% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was -155 million yuan, down 151.16% year-on-year [2]. - The company's debt ratio stood at 41.01% [2]. - Investment income was reported at 13.482 million yuan, while financial expenses amounted to 140 million yuan [2]. - The gross profit margin was 13.66% [2]. Market Activity - As of February 9, 2026, Bluefan Medical's stock closed at 6.02 yuan, with an increase of 0.84% [1]. - The turnover rate was 0.95%, with a trading volume of 94,600 hands and a transaction value of 56.912 million yuan [1]. - On February 9, the net inflow of main funds was 1.728 million yuan, accounting for 3.04% of the total transaction value [1]. - The net inflow of speculative funds was 1.7175 million yuan, representing 3.02% of the total transaction value [1]. - Retail investors experienced a net outflow of 3.4455 million yuan, which was 6.05% of the total transaction value [1].

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2026-013 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于预计触发可转债转股价格向下修正条件 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 8.50 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 （三）可转债转股期限 根据《蓝帆医疗股份有限公司公开发行可转换公司债券募集说明书》（以下简称 "《募集说明书》"）的规定，本次发行的可转债转股期自可转债发行结束之日（2020 年 6 月 3 日）满六个月后的第一个交易日（2020 年12 月 3 日）起至可转债到期日（2026 年 5 月 27 日）止。 （四）可转债转股价格调整情况 1、公司于 2021 年 5 月 17 日召开第五届董事会第十五次会议，于 2021 年 6 月 ...

Core Viewpoint - The successful listing of Beixin Life on the STAR Market marks a significant moment for domestic cardiovascular precision diagnostic device companies, highlighting the importance of global market access facilitated by Bluefan Medical, its largest overseas distributor [1][2]. Group 1: Company Overview - Beixin Life was listed at a price of 17.52 yuan per share, with its stock price surging over 200% on the first day, closing at 49.64 yuan, resulting in a market capitalization of nearly 20 billion yuan [1]. - Bluefan Medical has established itself as a key player in the global market for domestic medical devices, having built a unique channel for exporting innovative domestic products [1][2]. Group 2: Global Expansion Strategy - Bluefan Medical's acquisition of Baisheng International in 2018 allowed it to create a cardiovascular division, gaining access to a sales network covering over 100 countries and numerous international certifications [1][2]. - The company has developed a comprehensive platform for Chinese innovative medical devices, providing services such as global registration, clinical data support, and overseas sales network connections [2]. Group 3: Financial Performance - Beixin Life's overseas revenue saw a dramatic increase of 130.29% year-on-year in the first half of 2025, largely due to Bluefan Medical's channel support [2]. - Bluefan Medical's cardiovascular division achieved revenue exceeding 1.4 billion yuan in 2025, marking a growth of over 24% year-on-year and turning profitable [7]. Group 4: Product Development and Market Position - Bluefan Medical has established a full layout in the cardiovascular field, covering interventional cardiology, structural heart disease, neurointervention, and peripheral intervention, making it one of the few companies with comprehensive solutions in this area [4][5]. - The company has set up R&D centers in Germany, Singapore, and Shanghai, enabling it to respond effectively to market demands and enhance its competitive edge [3]. Group 5: Future Outlook - The listing of Beixin Life is seen as the beginning of a new logic for domestic medical device exports, emphasizing the need for effective market access and commercialization capabilities [7]. - Bluefan Medical is positioned as a "ferry operator" for domestic medical devices, facilitating the entry of innovative companies into global markets and potentially leading to a revaluation of its value as more partners join its export platform [7].

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations [2]. Financial Performance - For the first three quarters of 2025, Bluefan Medical reported a main revenue of 4.182 billion yuan, a year-on-year decrease of 10.15% [2]. - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year [2]. - The net profit after deducting non-recurring items was -364 million yuan, reflecting a significant decline of 46.25% [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 1.401 billion yuan, a decrease of 15.02% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -151 million yuan, a drastic decline of 153.64% [2]. - The single-quarter net profit after deducting non-recurring items was -155 million yuan, down 151.16% year-on-year [2]. - The company's debt ratio stands at 41.01%, with investment income of 13.482 million yuan and financial expenses of 140 million yuan [2]. - The gross profit margin is reported at 13.66% [2]. Market Activity - As of February 6, 2026, Bluefan Medical's stock closed at 5.97 yuan, with an increase of 1.19% [1]. - The trading volume was 86,300 hands, with a total transaction amount of 51.478 million yuan [1]. - On February 6, the net inflow of main funds was 3.8895 million yuan, accounting for 7.56% of the total transaction amount [1]. - The net inflow of speculative funds was 1.1186 million yuan, representing 2.17% of the total transaction amount [1]. - Retail investors experienced a net outflow of 5.0081 million yuan, which is 9.73% of the total transaction amount [1].